"We are pleased with the strong results for the third quarter, and the first nine months of 2016. These show QIAGEN's transformation is building momentum and a new sales growth trajectory is materializing. We are convinced these efforts to expand our leadership in molecular testing with a differentiated portfolio serving customers across the continuum from basic research to clinical healthcare will create significant value," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
Click here for the full press release
A PDF version of the full press release including financial tables can be downloaded here
Vice President Corporate Communications and Investor Relations
Dr. Sarah Fakih
Associate Director Investor Relations
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
SOURCE QIAGEN N.V.